Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of CSPC Pharmaceutical Group's Omalizumab Biosimilar?
Omalizumab Biosimilar is a monoclonal antibody commercialized by CSPC Pharmaceutical Group, with a leading Phase III program in Rhinosinusitis. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Teva Pharmaceutical Industries's Omalizumab Biosimilar?
Omalizumab Biosimilar is a monoclonal antibody commercialized by Teva Pharmaceutical Industries, with a leading Phase III program in Chronic Urticaria...